You have activated the high contrast version of the site. For more info on this topic, please visit this page.
A team from HUG and the University of Geneva has contributed to international research that has made it possible to develop a new therapeutic strategy for osteoporosis in menopausal women.
This revolutionary biological treatment kills two birds with one stone: on the one hand, it increases bone formation; on the other, it slows down bone resorption. After one year, its efficacy is clear: the number of vertebral and clinical fractures is reduced by 75% and 36% respectively.
Initially registered in the United States, this substance is set to be available in Europe and Switzerland by late 2017.